Diabetes drug could shield heart muscle during angioplasty
NCT ID NCT06342141
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether empagliflozin (Jardiance), a diabetes drug, can reduce the 'no-reflow' phenomenon—when blood flow fails to fully restore after angioplasty—in 162 heart attack patients. Participants receive a loading dose before the procedure and daily doses for 3 days. The study measures blood flow, heart strain, and infarct size. It is active but not recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Empagliflozin (Jardiance)
What this could lead to
If it works, this could point toward a new way to prevent heart muscle damage during angioplasty for heart attacks.
What could go wrong
This is a small, early-phase trial (162 people) and the drug is already approved for diabetes, so the heart benefit is unproven. It may not reduce no-reflow or improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NO-REFLOW PHENOMENON are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institute of Cardiology
Mexico City, Mexico City, 14080, Mexico